I agree that this site is using cookies. You can find further informations here.
X
Hammers, Hans J
200  results:
Search for persons X
?
1

Immunomodulatory response to neoadjuvant nivolumab in non-m..:

Singla, Nirmish ; Nirschl, Thomas R. ; Obradovic, Aleksandar Z....
Scientific Reports.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
2

Validation of the Lung Immune Prognostic Index (LIPI) as a ..:

Carril-Ajuria, Lucia ; Lavaud, Pernelle ; Dalban, Cecile...
European Journal of Cancer.  204 (2024)  - p. 114048 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Renal cell carcinoma histologic subtypes exhibit distinct t..:

Barata, Pedro ; Gulati, Shuchi ; Elliott, Andrew...
Journal of Clinical Investigation.  134 (2024)  11 - p. , 2024
Link: https://doi.org/10.1172/..
 
?
4

Treatment-free survival outcomes from the phase II study of..:

Atkins, Michael B ; Jegede, Opeyemi A ; Haas, Naomi B...
Journal for ImmunoTherapy of Cancer.  12 (2024)  4 - p. e008293 , 2024
Link: https://doi.org/10.1136/..
 
?
5

Highly variable timing renders immunotherapy efficacy and t..:

von Itzstein, Mitchell S. ; Yang, Yuqiu ; Wang, Yiqing...
Frontiers in Immunology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
6

First-Line Systemic Treatment Options for Advanced Renal Ce..:

, In: Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma,
Qin, Qian ; Brugarolas, James ; Hammers, Hans. - p. 269-292 , 2023
Link: https://doi.org/10.1007/..
 
?
7

The 5th Kidney Cancer Research Summit: Research Acceleratin..:

Choueiri, Toni K ; Pal, Sumanta K ; Lewis, Bryan...
The Oncologist.  29 (2023)  2 - p. 91-98 , 2023
Link: https://doi.org/10.1093/..
 
?
8

Phase II study of nivolumab and salvage nivolumab/ipilimuma..:

Atkins, Michael B ; Jegede, Opeyemi A ; Haas, Naomi B...
Journal for ImmunoTherapy of Cancer.  11 (2023)  3 - p. e004780 , 2023
Link: https://doi.org/10.1136/..
 
?
9

Conditional survival and long‐term efficacy with nivolumab ..:

Motzer, Robert J. ; McDermott, David F. ; Escudier, Bernard...
Cancer.  128 (2022)  11 - p. 2085-2097 , 2022
Link: https://doi.org/10.1002/..
 
?
10

Demonstrating Tumor Vascular Disrupting Activity of the Sma..:

Liu, Li ; Schuetze, Regan ; Gerberich, Jeni L....
Cancers.  14 (2022)  17 - p. 4208 , 2022
Link: https://doi.org/10.3390/..
 
?
11

Characterization and Management of Treatment-emergent Hepat..:

Rini, Brian I. ; Atkins, Michael B. ; Plimack, Elizabeth R....
European Urology Oncology.  5 (2022)  2 - p. 225-234 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Su1248: CHRONIC USE OF PROTON PUMP INHIBITORS IS ASSOCIATED..:

Yin, Jianyi ; Elias, Roy ; Peng, Lan...
Gastroenterology.  162 (2022)  7 - p. S-559-S-560 , 2022
Link: https://doi.org/10.1016/..
 
?
13

A Prospective Multicenter Evaluation of Initial Treatment C..:

Costello, Brian A. ; Bhavsar, Nrupen A. ; Zakharia, Yousef...
Clinical Genitourinary Cancer.  20 (2022)  1 - p. 1-10 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Phase II Trial of Stereotactic Ablative Radiation for Oligo..:

Hannan, Raquibul ; Christensen, Michael ; Hammers, Hans...
European Urology Oncology.  5 (2022)  2 - p. 216-224 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Neoadjuvant Nivolumab in Patients with High-risk Nonmetasta..:

Gorin, Michael A. ; Patel, Hiten D. ; Rowe, Steven P....
European Urology Oncology.  5 (2022)  1 - p. 113-117 , 2022
Link: https://doi.org/10.1016/..
 
1-15